Biotech | October 29, 2021
NH TherAguix releases new batch for AGuIX
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
The division is expected to grow to over a 100-member strong team by 2022
It is the first presbyopia-correcting lens implant for cataract surgery
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
U.S. FDA to decide whether to authorize a booster dose in the coming days
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Subscribe To Our Newsletter & Stay Updated
